These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer? Lamm DL Cancer Surv; 1998; 31():99-108. PubMed ID: 15281319 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst). Barreto L; Csizer Z; Sparkes JD Dev Biol Stand; 1992; 77():229-31. PubMed ID: 1426667 [TBL] [Abstract][Full Text] [Related]
7. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. De Jager R; Guinan P; Lamm D; Khanna O; Brosman S; De Kernion J; Williams R; Richardson C; Muenz L; Reitsma D Urology; 1991 Dec; 38(6):507-13. PubMed ID: 1836081 [TBL] [Abstract][Full Text] [Related]
8. BCG for bladder cancer. Med Lett Drugs Ther; 1991 Apr; 33(841):29-30. PubMed ID: 2002783 [No Abstract] [Full Text] [Related]
9. Carcinoma in situ. Lamm DL Urol Clin North Am; 1992 Aug; 19(3):499-508. PubMed ID: 1636234 [TBL] [Abstract][Full Text] [Related]
10. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer. Brosman SA; Lamm DL; van der Meijden AP; Debruyne FM Prog Clin Biol Res; 1989; 310():311-23. PubMed ID: 2672019 [TBL] [Abstract][Full Text] [Related]
11. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder. Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862 [TBL] [Abstract][Full Text] [Related]
12. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate. Palou J; Xavier B; Laguna P; Montlleó M; Vicente J Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354 [TBL] [Abstract][Full Text] [Related]
13. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. Palou J; Laguna P; Millán-Rodríguez F; Hall RR; Salvador-Bayarri J; Vicente-Rodríguez J J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902 [TBL] [Abstract][Full Text] [Related]
14. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207 [TBL] [Abstract][Full Text] [Related]
15. [Our experience in the treatment of superficial cancer of the bladder with BCG]. Martínez E; Díaz I; Salvador J; Viladoms JM; Zungri E; Solé-Balcells FJ Arch Esp Urol; 1989 May; 42(4):325-7. PubMed ID: 2782959 [TBL] [Abstract][Full Text] [Related]
16. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer. Sosnowski JT Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653 [No Abstract] [Full Text] [Related]
17. Optimal BCG treatment of superficial bladder cancer as defined by American trials. Lamm DL Eur Urol; 1992; 21 Suppl 2():12-6. PubMed ID: 1396941 [TBL] [Abstract][Full Text] [Related]